A Study to Compare Brachial Artery Reactivity and Cardiovascular Risk of a Treatment Simplification by Darunavir/Ritonavir (DRV/r) 800/100 mg Versus a Triple Combination Therapy Containing DRV/r in HIV-1 Infected Patients

NCT01391013 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

30

Enrollment

INDUSTRY

Sponsor class

Conditions

Human Immunodeficiency Virus 1

Interventions

DRUG: Darunavir(DRV)
DRUG: Ritonavir
DRUG: 2 nucleoside reverse transcriptase inhibitors (NRTIs)

Sponsor

Janssen-Cilag S.p.A.